Amy joined Eradigm in August 2023 as an associate consultant, bringing to the team her extensive experience in pharmaceutical market research and passion for transforming healthcare globally.
Amy previously worked at a data intelligence and consulting company, where her role was centred around conducting primary and secondary market research within the cardiovascular, metabolic disorders, and gender health spaces. She was responsible for producing syndicated market research reports and drug sales forecasts on therapeutic areas including endometriosis and atrial fibrillation, providing clients with strategic insights and high-quality market analysis. Prior to this, she also completed an internship at a life science strategy consulting firm, where she worked with pharmaceutical companies and biotech start-ups across a range of therapeutic area-specific projects.
Amy holds a first-class honours degree in neuroscience from UCL, where she developed a strong interest in neuropharmacology and the development of therapeutics for complex neurodegenerative diseases. Her final year dissertation focused on researching potential drug targets aimed at promoting neuroplasticity and enhancing motor recovery following ischemic stroke. Following this, Amy went on to complete her MSc in Drug Discovery and Pharmaceutical Management at UCL, where she gained extensive insight into the whole drug development process, from the initial drug target identification stages through to drug commercialisation and regulatory affairs. Her final research project analysed recent trends in the biotech financing environment, with a particular focus on IPOs.
In her free time, Amy enjoys playing tennis, trying out new fitness classes with friends, and attending the occasional park run on a Saturday morning. She also loves any food-related activities, whether that be exploring restaurants around London, or hosting friends and family for dinner where she can test out new recipes!